SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-07-29 |
| Reported value | $534,041,662 |
| Positions | 10 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| MeiraGTx Holdings plc | MGTX | COM | $164,791,427 | 12,197,737 |
| Inhibrx Biosciences, Inc. | INBX | COM | $109,713,489 | 1,157,926 |
| Novavax | NVAX | COM NEW | $64,814,131 | 6,880,481 |
| AnaptysBio | ANAB | COM | $55,479,398 | 821,917 |
| Odyssey Therapeutics Inc. | ODTX | COMMON STOCK | $37,268,786 | 1,991,918 |
| Agomab Therapeutics NV | AGMB | SPONSORED ADS | $36,124,586 | 2,783,096 |
| MapLight Therapeutics Inc. | MPLT | COM | $32,687,549 | 912,041 |
| First Tracks Biotherapeutics Inc. | TRAX | ORD SHS | $16,536,970 | 821,917 |
| Immuneering Corp | IMRX | CLASS A COM | $13,515,709 | 2,708,559 |
| Q32 Bio Inc. | QTTB | COM | $3,109,617 | 244,083 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.